Company research
Stimcell Energetics Inc.
CIK 1493712Updated Oct 15, 2026
SecuritySTME · OTC · equity
Historical securities (2)
CMXCD · OTC · equity · closed Dec 6, 2024CMXC · OTC · equity · closed Nov 5, 2024Name history
Cell MedX Corp. · through Oct 15, 2024Sports Asylum, Inc. · through Oct 9, 2014Plandel Resources, Inc. · through Mar 24, 2014
STME price & chart
Loading TradingView…
OTC:STME on TradingView ↗About the company
StimCell Energetics Inc. is a biotech company focused on the discovery, development and commercialization of therapeutic and non-therapeutic products that enhance cellular function, promote general wellness and alleviate health complications including, but not limited to: aging, insulin sensitivity, high blood pressure, neuropathy and kidney function. The Company’s main focus is on continued research and development of its eBalance® Technology and its eBalance® Home System.
In the news
No coverage from other publishers is available.
Recent filings
10-Q filing
Entry into a Material Definitive Agreement · Regulation FD Disclosure
Items 1.01, 7.01, 9.01
10-K filing
10-Q filing
Entry into a Material Definitive Agreement · Unregistered Sales of Equity Securities · Regulation FD Disclosure
Items 1.01, 3.02, 7.01, 9.01
Show 5 more recent filings
Financials
FY 2026 · USDSource
balance sheet · annual statements
| Line item | Q3 2026 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2027 | Q1 2026 | Q1 2025 | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 34,521Source | 17,110Source | 81,918Source | 52,345Source | 38,346Source | 60,946Source | 16,387Source | 22,397Source | 81,454Source | 21,222Source | 46,122Source | 103,270Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 1,712,941Source | 1,087,325Source | 791,864Source | 1,594,639Source | 1,021,051Source | 2,032,473Source | 1,410,336Source | 931,127Source | 1,892,774Source | 1,267,508Source | 872,577Source | 2,488,750Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 20,891Source | 19,816Source | 294,736Source | 20,891Source | 19,816Source | 21,141Source | 20,516Source | 297,236Source | 21,141Source | 20,141Source | 297,236Source | 62,923Source |
| Additional Paid in CapitalUSD | 9,395,841Source | 9,016,666Source | 8,663,581Source | 9,395,841Source | 9,016,666Source | 9,470,616Source | 9,266,216Source | 8,739,246Source | 9,470,616Source | 9,146,591Source | 8,736,081Source | 7,272,701Source |
| Retained Earnings (Accumulated Deficit)USD | -11,527,472Source | -10,642,227Source | -10,170,306Source | -11,436,906Source | -10,501,690Source | -11,926,449Source | -11,127,158Source | -10,362,182Source | -11,756,931Source | -10,861,556Source | -10,295,263Source | -10,152,777Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 65,827Source | 169,037Source | 60,550Source | 111,387Source | 116,010Source | 96,672Source | 79,984Source | 50,477Source | 87,361Source | 82,045Source | 68,998Source | 65,180Source |
| Liabilities and EquityUSD | 34,521Source | 17,110Source | 81,918Source | 52,345Source | 38,346Source | 60,946Source | 16,387Source | 22,397Source | 81,454Source | 21,222Source | 46,122Source | 103,270Source |
| Current liabilities: | ||||||||||||
| Accounts Payable, CurrentUSD | 319,927Source | 310,901Source | 277,054Source | 323,867Source | 316,282Source | 342,016Source | 296,001Source | 311,167Source | 356,302Source | 322,144Source | 288,891Source | 408,264Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 7,791Source | 8,803Source | 13,102Source | 15,402Source | 12,340Source | 41,183Source | 38,694Source | 6,705Source | 37,674Source | 26,954Source | 28,058Source | 36,560Source |
cash flow · annual statements
| Line item | Q4 2026 | Q4 2025 | Q3 2026 | Q3 2025 | Q2 2026 | Q2 2025 | Q1 2027 | Q1 2026 | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | -90,566Source | -140,537Source | -309,748Source | -139,508Source | -169,518Source | -265,602Source | -895,375Source | -566,293Source | -142,486Source | -495,042Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | -16,644Source | -27,482Source | 28,856Source | 42,857Source | 46,750Source | -14,064Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -108,995Source | -108,142Source | -312,081Source | -141,600Source | -145,898Source | -272,209Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 112,826Source | 100,000Source | 300,582Source | 112,858Source | 91,033Source | 346,364Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 3,826Source | -8,144Source | -11,524Source | -28,834Source | -54,880Source | 73,915Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 10,257Source | 6,678Source | 46,159Source | 33,821Source | 6,883Source | 6,437Source | 3,057Source | 14,581Source | 43,415Source | 98,295Source |
| Additional Financial Items | ||||||||||||
| AmortizationUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | -45,560Source | 53,027Source | 31,403Source | 65,533Source | 9,311Source | -2,061Source | 5,316Source | 13,047Source | 3,818Source | 118,593Source |
| Foreign Currency Transaction Gain (Loss), RealizedUSD | — | — | 30,146Source | -41,552Source | -21,548Source | -50,774Source | -6,704Source | 1,769Source | -5,501Source | -17,157Source | — | — |
| Foreign Currency Transaction Gain (Loss), UnrealizedUSD | — | — | -45,560Source | 53,027Source | 31,403Source | 65,533Source | 9,311Source | -2,061Source | 5,316Source | 13,047Source | 3,818Source | 118,593Source |
| General and Administrative ExpenseUSD | — | — | 8,208Source | 32,847Source | 163,598Source | 22,681Source | 67,296Source | 139,484Source | 382,560Source | 213,452Source | 160,935Source | 275,534Source |
| Operating ExpensesUSD | — | — | 71,908Source | 131,086Source | 293,046Source | 130,698Source | 146,558Source | 252,354Source | 826,027Source | 522,106Source | 268,352Source | 448,141Source |
income statement · annual statements
| Line item | Q4 2026 | Q4 2025 | Q3 2026 | Q3 2025 | Q2 2026 | Q2 2025 | Q1 2027 | Q1 2026 | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | — | — | — | — | — | — | — | — | 0Source | — |
| Earnings Per Share, BasicUSD per share | — | — | 0Source | -0.01Source | -0.01Source | -0.01Source | -0.01Source | -0.01Source | -0.04Source | -0.03Source | 0Source | -0.01Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 20,891,272Source | 19,816,272Source | 20,692,096Source | 19,816,272Source | 21,141,272Source | 20,319,261Source | 20,747,436Source | 19,843,258Source | 161,008,445Source | 62,923,063Source |
| Additional Financial Items | ||||||||||||
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | -45,560Source | 53,027Source | 31,403Source | 65,533Source | 9,311Source | -2,061Source | 5,316Source | 13,047Source | 3,818Source | 118,593Source |
| Foreign Currency Transaction Gain (Loss), RealizedUSD | — | — | 30,146Source | -41,552Source | -21,548Source | -50,774Source | -6,704Source | 1,769Source | -5,501Source | -17,157Source | — | — |
| General and Administrative ExpenseUSD | — | — | 8,208Source | 32,847Source | 163,598Source | 22,681Source | 67,296Source | 139,484Source | 382,560Source | 213,452Source | 160,935Source | 275,534Source |
| Gross ProfitUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 483Source |
| Interest ExpenseUSD | — | — | 18,658Source | 9,451Source | 16,702Source | 8,810Source | 22,960Source | 13,248Source | 69,348Source | 38,256Source | 61,651Source | 47,384Source |
| Management Fee ExpenseUSD | — | — | 22,500Source | 22,500Source | 22,500Source | 22,500Source | 22,500Source | 22,500Source | 90,000Source | 90,000Source | — | — |
| Operating ExpensesUSD | — | — | 71,908Source | 131,086Source | 293,046Source | 130,698Source | 146,558Source | 252,354Source | 826,027Source | 522,106Source | 268,352Source | 448,141Source |
| Research and Development ExpenseUSD | — | — | — | — | — | — | — | — | — | — | — | 89,220Source |
Filing attachments
stme_ex991.htm · 8-K · 2026-09-08
EX-99.1 3 stme_ex991.htm NEWS RELEASE DATED SEPTEMBER 8, 2026 News release dated September 8, 2026 StimCell Energetics Engages Stonegate Capital Markets as Non-Exclusive Advisor for Strategic Capital Market Transactions Vancouver, BC - September 8, 2026 - StimCell Energetics Inc. (OTCQB: STME) (“StimCell” or the “Company”), a biotech pioneer targeting cellular energy to enhance wellness, anti-aging, and longevity, is pleased to announce that it has entered into an Advisory Services Agreeme…
Read attachment ↗stme_ex991.htm · 8-K · 2026-03-20
EX-99.1 3 stme_ex991.htm NEWS RELEASE DATED MARCH 19, 2026 News release dated March 19, 2026 StimCell Energetics Engages Stonegate Capital Partners for Research Coverage and Institutional Investor Outreach Vancouver, BC - March 19, 2026 - StimCell Energetics Inc. (OTCQB: STME) (“StimCell” or the “Company”), a biotech pioneer targeting cellular energy to enhance wellness, anti-aging, and longevity, is pleased to announce that it has engaged Stonegate Capital Partners, Inc. (“Stonegate”) to …
Read attachment ↗stme_ex991.htm · 8-K · 2025-12-02
EX-99.1 2 stme_ex991.htm NEWS RELEASE DATED DECEMBER 2, 2025 News release dated December 2, 2025 StimCell Energetics Inc. Announces Study into eBalance® Device’s Impact on Neuronal Mitochondrial Function Vancouver, BC - December 2, 2025 - StimCell Energetics Inc. (OTC PINK: STME) (“StimCell” or the “Company”), a biotech pioneer targeting cellular energy to enhance wellness, anti-aging, and longevity, today announced the signing of a service agreement with the St. Boniface Hospital Albrecht…
Read attachment ↗stme_ex991.htm · 8-K · 2025-03-28
EX-99.1 4 stme_ex991.htm NEWS RELEASE DATED MARCH 26, 2025 News release dated March 26, 2025 StimCell Energetics Provides Sneak Peek at eBalance Redesign Progress and Announces Shares for Debt Transaction and the engagement of Independent Investor Relations Consultant Vancouver, BC - March 26, 2025 - StimCell Energetics Inc. (OTC PINK: STME) (“StimCell” or the “Company”), a biotech pioneer targeting cellular energy to enhance wellness, anti-aging, and longevity, is pleased to provide a pro…
Read attachment ↗stme_ex991.htm · 8-K · 2025-02-27
EX-99.1 2 stme_ex991.htm NEWS RELEASE DATED FEBRUARY 25, 2025 News release dated February 25, 2025 StimCell Energetics Partners with ADM Tronics to Redesign eBalance® Microcurrent Device for Home Use Innovative Redesign Brings Smaller, Cost-Effective Unit with Advanced Diagnostics to Consumers VANCOUVER, BC - February 25, 2025 - StimCell Energetics Inc. (OTC PINK: STME) (“StimCell” or the “Company”), a biotech pioneer targeting cellular energy to enhance wellness, anti-aging, and longevit…
Read attachment ↗stme_ex991.htm · 8-K · 2025-01-08
EX-99.1 2 stme_ex991.htm NEWS RELEASE DATED JANUARY 8, 2025 News release dated January 8, 2025 StimCell Energetics Inc. Signs Marketing Agreement with Think Ink Marketing Vancouver, BC, January 8, 2025, StimCell Energetics Inc. (OTC: STME) (“StimCell”, or the “Company”) a biotech company targeting cellular energy to promote anti-aging, longevity and general wellness, announces that it has signed an agreement with Think Ink Marketing Data & Email Services, Inc. (“Think Ink”) to provide publ…
Read attachment ↗